Sign In
Buy FLDM
$1.83
+0 (+0%)
At Close: Jul 20, 2022
Fluidigm (NASDAQ:FLDM) Downgraded by Zacks Investment Research
01:56am, Wednesday, 01'st Jul 2020
Fluidigm (NASDAQ:FLDM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday, Zacks.com reports. According to Zacks, “Flui
7 Stocks That Could Jump Higher
12:00am, Tuesday, 30'th Jun 2020
Stocks Analysis by Harry Boxer covering: Boeing Co, Bed Bath & Beyond Inc, Ballard Power Systems Inc, Fluidigm Corporation. Read Harry Boxer's latest article on Investing.com
Multi-Site Study of COVID-19 Patients Utilizing Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay
12:30pm, Monday, 29'th Jun 2020
Ten leading U.S. medical institutions are engaging in the study, sponsored by the National Institutes of Health (NIH) and entitled Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC). Investig
What a top N.J. recruit says about Rutgers ... and Greg Schiano’s relentless pursuit
01:00pm, Sunday, 28'th Jun 2020
In the end, can the Scarlet Knights steal one?
Hedge Funds Are Dumping Fluidigm Corporation (FLDM)
01:55am, Sunday, 28'th Jun 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Integrated Genetics Lab Services Conducting COVID-19 Testing in Spain Utilizing Fluidigm Biomark HD Platform
12:30pm, Wednesday, 24'th Jun 2020
iGLS Among Labs Chosen by Spanish Health Authorities to Expand SARS-CoV-2 Screening End-to-End Workflow from Extraction through Real-Time PCR Using Fluidigm.
Two Sigma Investments LP Has $1.19 Million Stake in Fluidigm Co. (NASDAQ:FLDM)
08:10am, Tuesday, 23'rd Jun 2020
Two Sigma Investments LP trimmed its position in shares of Fluidigm Co. (NASDAQ:FLDM) by 22.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commissi
Fluidigm (NASDAQ:FLDM) Stock Rating Lowered by Zacks Investment Research
01:48am, Friday, 19'th Jun 2020
Fluidigm (NASDAQ:FLDM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “F
New Collaboration with Bethyl Laboratories Expands Antibody Offerings for Hyperion Imaging System
12:30pm, Wednesday, 17'th Jun 2020
“Tools for understanding the immune system are more important than ever as researchers work to improve human health, particularly in responding to challenges posed by COVID‑19,” said Andrew Quon
Fluidigm Files for FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Test for COVID-19
12:00am, Saturday, 13'th Jun 2020
The test, developed in collaboration with scientists at the McDonnell Genome Institute and the Department of Genetics at Washington University School of Medicine in St. Louis, provides an easy-to-admi
Occidental Petroleum Cuts Quarterly Dividend to 1 Cent | MarketScreener
06:02pm, Friday, 29'th May 2020
The findings may help define a population of COVID-19 patients at high risk for becoming critically ill, and they suggest a possible benefit from anti-inflammatory therapies. The study, available onl
Fluidigm to Present at Upcoming Health Care Investor Conferences
08:02pm, Wednesday, 13'th May 2020
SOUTH SAN FRANCISCO, Calif., May 13, 2020 -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.
Why Fluidigm Stock Is Soaring Again Today
03:44pm, Tuesday, 12'th May 2020
Investors appear to be banking on the company winning FDA emergency use authorization for its Biomark system in COVID-19 testing.
6 Stock Charts To Watch: AMRS, CYTK, DRNA, LX, MRNA, VAPO
12:00am, Tuesday, 12'th May 2020
Stocks Analysis by Harry Boxer covering: SPDR S&P 500, Amyris Inc, BioCryst Pharmaceuticals Inc, Cytokinetics Inc. Read Harry Boxer's latest article on Investing.com
